AstraZeneca and Intomics have signed an agreement to accelerate AZ's drug discovery programs. Intomics will assist in drug discovery projects by providing data, methods, and tools for integrating and analyzing highly complex proprietary clinical, biological and chemical data. The collaboration spans a range of research projects. The financial terms of the agreement were not disclosed.
“We are delighted to assist AstraZeneca with their very exciting research projects. We see a great synergy in combining our data analysis expertise with AstraZeneca’s profound knowledge in some very important disease areas. The collaboration will help facilitate efficient drug discovery projects with shorter turnaround time and improved results,” said Thomas S. Jensen, chief executive officer of Intomics.